Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
COVID-19 Outcome Prediction Algorithm
NCT05471011 · View on ClinicalTrials.gov ↗
Study Summary
Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in hospitalized COVID-19 patients broadly reflecting US demographics who are at increased risk of adverse outcomes from COVID-19 using both clinical and molecular data. We will enroll patients from a hospitalized civilian population in one of the country's largest metropolitan areas and a representative National Veteran's population.
Conditions Studied
Interventions
- OTHER Blood and nasal swab sampling
Study Locations (7)
California
- VA Greater Los Angeles Healthcare System — Los Angeles
- Ronald Reagan UCLA Medical Center — Los Angeles
- Olive View-UCLA Education & Research Institute — Sylmar
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance
Georgia
- Atlanta VA Medical Center — Decatur
New York
- Bronx VA Medical Center — The Bronx
Texas
- Michael E. DeBakey VA Medical Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2026-05-31 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05471011
The ClinicalTrials.gov registry entry for NCT05471011 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 829 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention — of which Blood and nasal swab sampling is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05471011 reports 7 study locations spanning 4 distinct geographic areas — top geographies include California, Georgia, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05471011 about?
NCT05471011 is a clinical study titled "COVID-19 Outcome Prediction Algorithm". Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in ...
What is the current status of trial NCT05471011?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2022-08-08. Estimated completion is 2026-05-31.
What conditions does trial NCT05471011 study?
This clinical trial studies the following conditions: COVID-19, Long COVID, Frailty Syndrome, Post Acute Sequelae of COVID-19, Organ Dysfunction Syndrome, Multiple. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05471011?
The interventions under investigation include: Blood and nasal swab sampling (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05471011?
This trial is sponsored by University of California, Los Angeles, which has 829 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05471011 being conducted?
This trial has 7 study locations across California, Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.